Bill
A 1439
Provides that purchase of insulin is not subject to deductible; requires health insurers to limit copayments and coinsurance for insulin; requires insulin manufacturers to submit report to Commissioner of Banking and Insurance.
2024-2025 Regular Session
Introduced by Clinton Calabrese and 6 co-sponsors
Eliminates insulin deductibles, caps copayments, and mandates manufacturer pricing disclosures to reduce patient medication costs in New Jersey.
Introduced in the Assembly, Referred to Assembly Financial Institutions and Insurance Committee